
Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

New data show heat- and pressure-treated peanuts significantly reduce IgE binding, skin test reactivity, and oral challenge severity in allergic patients.

This first episode of 2026 highlights ways to advocate for change in healthcare, empowering each other and patients while navigating systemic challenges.

Fortis discusses new data that challenge the use of bronchodilator response as a tool for distinguishing asthma from COPD.

Lund discusses a recent study detailing the comparatively lower greenhouse gas emissions caused by preventive care versus diabetes management.

MacDougall discusses the Family Heart Foundation’s recent study indicating that very few adults with ASCVD are receiving guideline-directed therapy.

COPDGene data show bronchodilator response more accurately predicts FEV₁ decline and disease progression than polygenic risk scores, including among smokers with preserved spirometry.

Palaniappan explains what steps to take in managing cardiovascular disease risk among a population that does not adhere to the Life’s Essential 8 guidelines.

A pair of hepatology experts discuss the shifting therapeutic landscape in PBC, lingering unmet needs, and where the field may be heading next.

Lungcast reflects on pulmonology in 2025, looking back at topics ranging from ALA's ‘State of the Air’ report to the lung-gut microbiome.

This segment of the latest Skin of Color Savvy episode highlights a conversation between Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS.

Machine models identified 2% of CBCs as possibly contaminated and flagged 6–9% of inpatient transfusions as potentially unnecessary, explains Maucione.

Despite being considered superior to in-clinic measurements, a substantial number of patients do not follow the HBPM guideline recommendations of 12 readings per week.

This segment of Liver Lineup features an in-depth discussion on hepatocellular carcinoma screening in patients with cirrhosis.

Tim Pflederer, explains how nephrologists can help patients with CKD and ESKD navigate the 2025–2030 Dietary Guidelines, including managing protein, potassium, and phosphorus intake.

Adjunctive lumateperone 42 mg improves remission, relieves anxiety and sleep symptoms, and shows sustained safety in patients with treatment-resistant MDD.

Balentine explains the unique challenges of AI implementation in surgery and reviews his research on current barriers to real-world uptake.

Updated federal guidelines highlight protein intake, with Tim Pflederer emphasizing the importance of individualized nutrition strategies for CKD patients

This segment of the most recent episode of Skin of Color Savvy highlights a conversation between Shawn Kwatra, MD, and Andrew Alexis, MD, MPH.

This new episode from January 2026 features a compilation of 3 clips from the most viewed episodes of 2025.

This segment of Liver Lineup features an in-depth discussion on transplant access with MELD 3.0 and new research about potential disparities it introduces.

Lumateperone 42 mg plus antidepressants boosts remission rates and sustains symptom improvement in MDD patients, says Michael E. Thase, MD.

In a 26-week head-to-head study, adjunctive seltorexant led to less weight gain and improved insulin sensitivity trends compared with quetiapine XR in MDD with insomnia.

Sinha describes data supporting the safety and utility of a fasting-mimicking diet in Crohn’s disease and explores what may be next in this line of research.

Sinha explains current unmet needs in mild Crohn’s, the shortcomings of steroids for these patients, and what benefits a fasting-mimicking diet may offer.

Berotralstat becomes the first once-daily oral prophylactic option for long-term prevention of hereditary angioedema in children aged 2–11 years.

Lee describes misconceptions about ALD, the importance of multidisciplinary care, and what the future of pharmacotherapy for this disease may hold.

The SWITCH phase 1 trial aims to determine the optimal time to switch medications to minimize thrombotic risk and avoid leaving patients untreated.

Scott describes current unmet needs in IBD diagnosis and monitoring but points to the potential of a new GzmA activity-based optical assay.

This episode of Skin of Color Savvy was filmed on-site at the Skin of Color Society's 'Meeting the Challenge Summit' in Washington, DC.